SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe E. who wrote (5768)12/15/1998 12:23:00 PM
From: scaram(o)uche   of 6136
 
TD:

Joe nailed it, IMO. I feel that the target is prophylaxis of high risk populations.

Long term? Let's see what the toxicity profiles look like. I don't get them frequently, but colds hit me hard, and the sequelae make me miserable. I'd love something that would take the hard edge off of an occasional rhino encounter. Small market initially (if and when!!), but the patent has a long, long run. :-)

Yes, companies like Bayer (Miles) were chasing rhino for ages, but..... wrong target, IMO.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News